Savara Inc. (NASDAQ:SVRA) Receives $10.14 Average Price Target from Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $10.1429.

Several research firms have recently weighed in on SVRA. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th. Oppenheimer began coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating on shares of Savara in a report on Monday, March 16th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Swedbank AB grew its position in shares of Savara by 54.5% in the fourth quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 300,000 shares during the last quarter. F m Investments LLC lifted its position in shares of Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company’s stock worth $4,093,000 after buying an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Savara in the 4th quarter valued at approximately $10,182,000. Rosalind Advisors Inc. boosted its position in Savara by 50.7% in the third quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after buying an additional 1,345,056 shares in the last quarter. Finally, Eversept Partners LP bought a new stake in Savara during the 4th quarter worth $1,026,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

SVRA stock opened at $6.29 on Friday. Savara has a 1-year low of $2.24 and a 1-year high of $7.01. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.29 billion, a PE ratio of -11.23 and a beta of 0.24. The business’s 50-day moving average price is $5.42 and its two-hundred day moving average price is $5.56.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, research analysts forecast that Savara will post -0.57 earnings per share for the current year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.